While clinical research is at the forefront of critical medical advancements, traditional ways of conducting trials come with significant challenges. The struggle to create a clinician-friendly approach has made workforce retention an ongoing pain point and geographical barriers impact the standardization of data collection across clinical sites. An innovative approach has emerged in response to these challenges: The integration of Diversified Clinical Trials (DCT).
An Overview: Diversified Clinical Trials
DCT aims to enhance the efficiency and comprehension of study results by including a more diverse participant population. This is crucial as traditional clinical trials often underrepresent certain demographic groups, leading to results that may not be applicable to the broader population.
Today, there are already a variety of DCT approaches being implemented:
- Remote and Virtual Trials leverage technology to allow remote engagement, reducing geographical barriers and enabling more diverse participation.
- Decentralized Trials engage local healthcare providers or facilities for aspects of the trial, making participation more accessible and convenient by minimizing travel.
- Pragmatic Trials evaluate treatments in real-world settings, often involving a broader patient population and assessing outcomes that matter to patients and healthcare providers.
- Patient-Centric Trials prioritize patient preferences, needs, and experiences, which can enhance recruitment and retention.
- Community-Based Participatory Research engages communities in the design and conduct of research to address health disparities and improve relevance to the community's needs.
When it comes to implementation, it’s important to note that there isn't a single "best" or "easiest to implement" model for DCT. Remote and virtual trials might be more feasible with advancements in technology but could raise patient privacy and digital access issues. Pragmatic trials and patient-centric approaches are often viewed favorably but might require significant buy-in from healthcare providers and institutions. Ultimately, the model should be guided by specific research goals, therapeutic area, available resources, regulatory considerations, and characteristics of the patient population being targeted.
However, there’s another DCT model with a patient-centric approach that has delivered consistent success: The hub-and-spoke model. This model better mitigates the lack of diversity among participants, addresses common patient complaints, and produces comprehensive results.
As clinical research continues to evolve, we’re partnering with customers to put them ahead of industry peers in creative physician and patient engagement.
The Hub-and-Spoke Model
At the core of this approach is the hub-and-spoke network, a collaborative framework where a Principal Investigator (PI) serves as the central hub, orchestrating multiple satellite or remote MD offices as spokes. The PI assumes responsibility for the protocol development, overall study oversight, data analysis, regulatory compliance, and in many cases, recruitment of medical colleagues on a global scale. Satellite MD offices play a pivotal role in recruiting patients, executing study interventions, and adhering to established protocols.
Benefits of the Hub-and-Spoke Model
Finding and opening clinical trials to more physicians and patients makes sense from a medical, demographic, and patient satisfaction perspective. Among these advantages, the hub-and-spoke model yields benefits to both the clinical trial process and patients, including:
- Efficiencies of Scale. By centralizing core responsibilities with the PI and distributing the study’s execution across local, national, and international satellite sites, the model optimizes and significantly expands resources and coordination.
- Protocol Standardization. As standardized data collection methods are employed across various clinical sites, streamlined analysis saves valuable time and resources.
- Elimination of Geographical Barriers. Broadening potential recruitment is one of the most significant advantages. By allowing patients to participate through local MD offices, access increases, paving the way for the diversity needed to develop effective treatments.
- Reduction of Attrition and Dropout. The hub-and-spoke model tackles patient attrition head-on by reducing travel requirements, offering flexible scheduling, and providing interventions with local offices. As a result, patients are more likely to stay engaged and committed to the trial.
- Improved Physician Recruitment. DCTs can offer remote clinical trial physicians opportunities to participate in cutting-edge research while remaining in their own practices and reducing the burden of the entire trial process. This allows a broader pool of skilled professionals to participate in clinical research, benefiting patients and the medical community.
- Enhanced Diversity. The geographic inclusivity of this approach will lead to outcomes more representative of the national US population, aligning with the major DEI commitments that pharmaceutical companies have made to the FDA and other regulatory bodies.
The Impact of Model Reinvention
In clinical research, patient and physician recruitment and retention are pivotal to the success of clinical trials—and the advancement of medical science. Traditional clinical trial models no longer meet the needs of core constituent groups or the pharma industry at large. As clinical research continues to evolve, we’re partnering with customers to put them ahead of industry peers in creative physician and patient engagement.
In terms of innovative approaches, the hub-and-spoke model shows great promise, being recognized for its ability to expand MD recruitment, drive patient participation, and contribute to DEI efforts. Its ability to optimize existing resources, broaden access, and foster inclusivity makes this approach a welcome change to traditional models. Taken together, DCT and the hub-and-spoke model have the potential to revolutionize the way clinical trials are conducted, improving outcomes and touching the lives of millions of patients who will be impacted by newly developed treatments.
RELATED INDUSTRIES
